01:05:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-10-30 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 Årsstämma 2024
2024-04-24 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-26 X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2023-01-12 Extra Bolagsstämma 2022
2022-11-04 Kvartalsrapport 2022-Q3
2022-08-05 Kvartalsrapport 2022-Q2
2022-05-30 Kvartalsrapport 2022-Q1
2022-05-23 X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-24 X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-12 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-14 X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-11 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-11-08 Extra Bolagsstämma 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-13 X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-16 X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-11-03 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-02-09 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga patienttillstånd inom kroniska inflammatoriska sjukdomar, samt diverse ledskador. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Lund.
2023-04-03 07:01:00

The Nomination Committee of SynAct Pharma (“SynAct”) intends to propose to the Annual General Meeting on May 25, 2023, that the existing board member Uli Hacksell is elected as new Chairman of the Board of Directors and that Thomas von Koch is elected as new member of the Board of Directors.

The Board of Directors of SynAct has resolved to appoint the current Chairman of the Board of Directors, Torbjørn Bjerke, as new CEO effective as from the Annual General Meeting on May 25, 2023. In connection herewith, Torbjørn Bjerke will resign as Chairman and member of the Board of Directors. In view of this, the Nomination Committee has resolved to propose to the Annual General Meeting that the existing Board member Uli Hacksell is elected as the new Chairman of the Board of Directors. The Nomination Committee will further propose that Thomas von Koch is elected as new ordinary Board member and that all other existing Board members, except for Torbjørn Bjerke, are re-elected.

Uli Hacksell has been a member of the SynAct Board of Directors since 2020. He has more than 30 years of experience from executive positions in major pharmaceutical and biotech companies and more than 10 years of experience as the CEO of publicly listed companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a professor of organic chemistry at Uppsala University. He holds a PhD from Uppsala University.

Dr. Hacksell is Chairman of the board of Medivir and Annexin Pharmaceuticals, and a board member of InDex Pharmaceuticals and Active Biotech.

Thomas von Koch has extensive financial and leadership experience spanning over 30 years. Mr. von Koch is currently chairman of the board at Swedish medical device company Bactiguard, a company he co-founded, and of which remains principal owner. Following 12 years at Investor AB, where he worked with corporate finance and mergers and acquisitions, he joined the global investment giant EQT as one of its initial team members. Mr. von Koch was CEO and Managing Partner of EQT from 2014 to 2019 and remains Deputy Managing Partner in EQT Partners AB.

Mr. von Koch has a Master of Science in Business Administration from the Stockholm School of Economics and extensive board, partnering and merger and acquisition experience. He currently has a holding of 1,118,210 shares and furthermore also owns 50 per cent of the shares in a company which owns additionally 159,744 shares in SynAct. His aggregate direct and indirect holdings in SynAct hence amounts to 1,198,082 shares or approximately 3.77 per cent of the total number of shares in SynAct.

Jens Bager, Chairman of the Nomination Committee, said: “Thomas has an impressive career, and we are excited to welcome him to the SynAct Pharma board. His extensive leadership, finance experience and network of business and financial contacts will be invaluable as the company continues on its growth path and executes on its long-term plans.

The members of the Nomination Committee are Jens Bager (appointed by GL Capital AB, Chairman of the Nomination Committee), Niels Ankerstjerne Sloth (appointed by Bioinvest ApS), Per Colleen (appointed by TomEnterprise Public Capital AB), and Torbjørn Bjerke (Chairman of the Board).

Information about the proposed Board members, the Nomination Committee’s complete proposal and the Nomination Committee’s statement will be made available on SynAct Pharma’s website www.synactpharma.com, in connection with the publication of the notice of the Annual General Meeting.

The information was submitted, through the agency of the contact person below, for publication at 07:01 a.m CEST on April 3, 2023.